A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma

Digestive and Liver Disease

Volumn 41, Issue 1, 2009, Pages 36-41

  Hui, Dong ^a   Qiang, Li ^a   Jian, Wang ^a   Ti, Zhang ^a   Da Lu, Kong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; Cytokine induced killer cells; Hepatectomy; Hepatocellular

Indexed keywords

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SINGLE BLIND PROCEDURE; SURVIVAL RATE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; RECURRENCE; RISK FACTORS;

EID: 57449105089     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2008.04.007     Document Type: Article

References (25)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Qiang L., Huikai L., Butt K., Wang P.P., and Hao X. Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg 30 (2006) 439-445
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 94 (2001) 153-156
4. Avila M.A., Berasain C., Sangro B., and Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25 (2006) 3866-3884
5. Zoll B., Lefterova P., Csipai M., Finke S., Trojaneck B., Ebert O., et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 47 (1998) 221-226
6. Schmidt-Wolf I.G., Negrin R.S., Kiem H.P., Blume K.G., and Weissman I.L. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174 (1991) 139-149
7. Lai E.C., Fan S.T., Lo C.M., Chu K.M., Liu C.L., and Wong J. Hepatic resection for hepatocellular carcinoma: an audit of 343 patients. Ann Surg 221 (1995) 291-298
8. Bathe O., Scudamore C., Caron N.R., et al. Resection of hepatocellular carcinoma. In: Okuda K., and Tabor E. (Eds). Liver cancer (1997), Churchill Livingstone, New York 511-529
9. Bismuth H., Chiche L., Adam R., Castaing D., Diamond T., and Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 (1993) 145-151
10. Lai E.C., Lo C.M., Fan S.T., Liu C.L., and Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133 (1998) 183-188
11. Ono T., Yamanoi A., Nazmy El Assal O., Kohno H., and Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91 (2001) 2378-2385
12. Lo C.M., Liu C.L., Chan S.C., Lam C.M., Poon R.T., Ng I.O., et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245 (2007) 831-842
13. Kubo S., Nishiguchi S., Hirohashi K., Tanaka H., Shuto T., Yamazaki O., et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized controlled trial. Ann Intern Med 134 (2001) 963-967
14. Lau W.Y., Leung T.W., Ho S.K., Chan M., Machin D., Lau J., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353 (1999) 797-801
15. Zhang Z., Liu Q., He J., Yang J., Yang G., and Wu M. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89 (2000) 2606-2612
16. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma: Hepatoma Prevention Study Group. N Engl J Med 334 (1996) 1561-1567
17. Ren Z.G., Lin Z.Y., Xia J.L., Ye S.L., Ma Z.C., Ye Q.H., et al. Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 10 (2004) 2791-2794
18. Kawata A., Une Y., Hosokawa M., Wakizaka Y., Namieno T., Uchino J., et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 18 (1995) 257-262
19. Lygidakis N.J., Pothoulakis J., Konstantinidou A.E., and Spanos H. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 15 (1995) 543-550
20. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356 (2000) 802-807
21. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 21 (1993) 1673-1679
22. Wang F.S., Liu M.X., Zhang B., Shi M., Lei Z.Y., Sun W.B., et al. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 8 (2002) 464-468
23. Hongeng S., Petvises S., Worapongpaiboon S., Rerkamnuaychoke B., Pakakasama S., and Jootar S. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 77 (2003) 175-179
24. Jiang J., Xu N., Wu C., Deng H., Lu M., Li M., et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 26 (2006) 2237-2242
25. Leemhuis T., Wells S., Scheffold C., Edinger M., and Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11 (2005) 181-187